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Natalizumab, a humanized monoclonal antibody (mAb) against α4integrin, reduces the number of dendritic cells (DC) in cerebral perivascular spaces in multiple sclerosis (MS). Selective deletion of α4integrin in CD11c+ cells should curtail their migration to the central
nervous system (CNS) and ameliorate experimental autoimmune
encephalomyelitis (EAE). We generated CD11c.Cre+/−ITGA4fl/fl
C57BL/6 mice to selectively delete α4-integrin in CD11c+ cells. Active
immunization and adoptive transfer EAE models were employed
and compared with WT controls. Multiparameter flow cytometry
was utilized to immunophenotype leukocyte subsets. Single-cell
RNA sequencing was used to profile individual cells. α4-Integrin expression by CD11c+ cells was significantly reduced in primary and
secondary lymphoid organs in CD11c.Cre+/−ITGA4fl/fl mice. In active
EAE, a delayed disease onset was observed in CD11c.Cre+/−ITGA4fl/fl
mice, during which CD11c+CD88+ cells were sequestered in the
blood. Upon clinical EAE onset, CD11c+CD88+ cells appeared in the
CNS and expressed CD317+. In adoptive transfer experiments,
CD11c.Cre+/−ITGA4fl/fl mice had ameliorated clinical disease phenotype associated with significantly diminished numbers of CNS
CD11c+CD88+CD317+ cells. In human cerebrospinal fluid from subjects with neuroinflammation, microglia-like cells display coincident
expression of ITGAX (CD11c), C5AR1 (CD88), and BST2 (CD317). In
mice, we show that only activated, but not naïve microglia
expressed CD11c, CD88, and CD317. Finally, anti-CD317 treatment
prior to clinical EAE substantially enhanced recovery in mice.
multiple sclerosis

Materials and Methods
Generation of CD11c.Cre+/− α4-Integrin–Deficient Mice. Female homozygote
ITGA4-floxed (ITGA4fl/fl) C57BL/6 mice, generated by Thalia Papayannopoulou, University of Washington, Seattle, WA (5), were crossed with commercially available CD11c/Cre+ C57BL/6 males (http://jax.org; stock no: 008068)
(6), and the progeny were backcrossed to generate CD11c+/− ITGA4fl/fl mice.
These mice were extensively characterized (7). Each generation of mice was
genotyped via genomic PCR using CD11c-specific primers. C57BL/6 WT mice

Significance
The bone marrow-derived CD11c+CD88+CD317+ myeloid cells
within the central nervous system are associated with clinical experimental autoimmune encephalomyelitis. Transcriptional analyses identify ITGAX- (CD11c), C5AR1- (CD88), and BST2- (CD317)
expressing cells as a distinct myeloid subset in human cerebrospinal fluid. The disease-propagating effects of these cells in
experimental autoimmune encephalomyelitis can be effectively
antagonized using anti-CD317 monoclonal antibody therapy.
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through an impaired reactivation of CNS-specific CD4+ T cells
and a reduction of direct inflammatory effects exerted by these
cells.
To further understand the role of CD11c+ cells within the CNS
during CD4+ T cell-mediated CNS autoimmunity, we generated
and characterized CD11c.Cre+/−ITGA4fl/fl mice, which lack α4-integrin
expression in CD11c+ cells. We identified CD11c+CD88+CD317+ as
mediators of persistent clinical EAE, and propagators of inflammation
within the CNS.

utoimmune disorders of the central nervous system (CNS),
including multiple sclerosis (MS), are thought to be mediated
by aberrant adaptive immune responses against self-antigens. In
experimental autoimmune encephalomyelitis (EAE), a model of
MS, activated myelin-reactive CD4+ T helper cells are the main
drivers of disease activity (1). In active EAE, dendritic cells (DC)
are professional antigen-presenting cells (APC) at the inoculation
site, namely in draining lymph nodes and other secondary lymphoid organs, where they present myelin autoantigen to naïve
CD4+ T lymphocytes (2). Myeloid APC within the CNS are essential for the reactivation and retention of these autoreactive
CD4+ T cells, and for perpetuation of disease activity. Specifically,
myeloid cells within cerebral perivascular spaces previously considered DC based solely on their expression of CD11c are sufficient
to permit EAE (3). Myeloid APC, including DC, use α4-integrin to
gain access to sites of ongoing inflammation. We previously showed
that the number of DC was significantly reduced in cerebral perivascular spaces in autopsy material of an MS patient treated with
natalizumab, a humanized monoclonal antibody (mAb) against α4integrin (4). Conceivably, antagonizing or diminishing the function
of α4-integrin selectively in myeloid cells should ameliorate EAE
PNAS 2021 Vol. 118 No. 14 e2014492118
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were purchased from the Jackson Laboratories. C57BL/6 WT mice were bred
and maintained in a pathogen-free facility at the University of Texas
Southwestern Medical Center according to guidelines provided by the National Institute of Health and our institution. Male and female mice were
utilized for experiments. Specifically, all experiments were carried out exclusively either with female or male mice, and no sex-specific effects were
observed. We observed no differences regarding disease scores, cellular
composition, or any of the biochemical and cellular outcomes between the
two sexes. The University of Texas Southwestern Institutional Animal Care
and Use Committee approved all experiments and procedures.
Peptides. Mouse myelin oligodendrocyte glycoprotein peptide 35–55 (MOGp35-55)
(MEVGWYRSPFSRVVHLYRNGK), synthesized by Fmoc chemistry by Quality
Controlled Biochemicals and CS Bio, was utilized for active immunization EAE.
Experimental Autoimmune Encephalomyelitis. To induce active EAE, experimental mice aged 8 to 12 wk were immunized subcutaneously with myelin
MOGp35-55 (100 μg/100 μL per mouse), emulsified in an equal volume of
complete Freund adjuvant (CFA) containing 4 mg/mL H37Ra Mycobacterium
tuberculosis (Difco, BD) in each flank as described previously (8). Upon immunization and 48 h later, experimental animals received intraperitoneal
injection of 200 ng PTX in 200 μL phosphate buffered saline (PBS).
For adoptive-transfer EAE, donor cells were harvested from the draining
axillary and inguinal lymph nodes of female WT C57BL/6 mice 10 d after active
immunization with MOGp35-55, as described above, and single-cell suspensions
were prepared. CD4+ T cells, including MOGp35-55–reactive T cells, were purified via negative selection (EasySep Mouse CD4+ T cell Isolation Kit, StemCell
Technologies, Lot: 18H94653). Purified CD4+ T cells were cultured for 72 h with
interleukin-12 (IL-12) and MOGp35-55. Subsequently, cultured cells were injected to recipient mice (10 × 106 cells per mouse intraperitoneally).
For treatment experiments, mice were injected with 250 μg of a rat antimouse IgG2bĸ anti-CD317 mAb (BioxCell, clone 927) intraperitoneally on days
7 and 8 postimmunization. The anti-CD317mAb is a blocking IgG2b variant.
Specifically, we administered this isotype to avoid complement fixation and
Ab-mediated depletion of CD317+ cells. As controls, we decided to deliver two
equal volumes of vehicle (PBS) by intraperitoneal injections on days 7 and 8.
All experimental animals were observed at least twice daily and disease
severity scores were recorded based on a standard EAE scoring system; briefly:
0 = no observable clinical signs, 1 = loss of tail tone or mild hind limb weakness
but not both, 2 = limp tail and mild hind limb weakness, 3 = moderate hind
limb weakness with or without unilateral hind limb paralysis, 4 = complete
bilateral hind limb paralysis, 5 = bilateral hind limb paralysis with fore limb
weakness or moribund state or death. The following cumulative interventions
were performed for all experiment animals. Moist chow was provided daily
once the animal reached clinical score of 3. Regular palpation of the bladder
and manual assistance with urination was performed for animals with disease
score of 4; animals with EAE score of 4 were kept separated from cage mates
with lower scores. Persistence of disease severity at EAE score 4, for at least
72 h or observation of EAE score 5 regardless of initiation time warranted
killing using carbon dioxide asphyxiation followed by cervical dislocation as
the secondary physical method. In our current animal facility, and with our
current EAE induction protocol, immunized mice on the C57BL/6 background
typically exhibit peak disease severity after 15 d. This is followed by a persistent plateau of clinical disease severity. For this reason, we obtained biological
samples from experimental animals on day 18.
Isolation of Lymph Node Cells and Splenocytes. Cells from lymph nodes and
spleen were isolated by pressing through a 70-μm nylon mesh cell retainer as
described previously (8–10). Cells were treated with red blood cell (RBC) lysis
buffer (Sigma-Aldrich), washed twice with cold PBS, and resuspended in PBS
for counting by hemocytometer.
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Bone Marrow Cell Isolation. Bone marrow cells were isolated from the femurs
and tibias of mice as described previously (10). Bones were crushed with a
mortar and pestle. Specimens were then passed through a 70-μm nylon mesh
cell retainer. Cells were treated with RBC lysis buffer (Sigma-Aldrich),
washed two times with cold PBS, and resuspended in PBS for counting with
hemocytometer.
Enzymatic CNS Digestion. Mice were anesthetized with 250 mg/kg intraperitoneal injection of tribromoethanol (Avertin, Sigma Aldrich) solution and
perfused with PBS through the left ventricle, as described previously (8).
Brains were dissected from the skull and spinal cords were flushed from the
spinal column with PBS. Tissues were finely minced using a sterile scalpel and
homogenized in cold PBS. We used a commercially available neural tissue
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dissociation kit for enzymatic dissociation following the manufacturer’s
protocol (Miltenyi Biotec). Specimens were subsequently washed with cold
PBS; 37% Percoll PLUS (GE Healthcare) gradient was used to remove the
residual myelin. The myelin-free single-cell suspensions were counted with
hemocytometer.
Separation of Blood Leukocytes. Submandibular bleeding of actively immunized mice was performed on day 12 postimmunization. Approximately
400 μL of peripheral blood was collected in EDTA tubes from each mouse.
The samples from CD11c.Cre+/−ITGA4fl/fl mice and WT controls were pooled
separately. The pooled samples were diluted with 1:1 ratio with PBS and
slowly added on top of 100% Ficoll in a 5-mL cryotube. Ficoll gradient
layering allowed to separate peripheral blood mononuclear cells (PBMC) without
the need for RBC lysis. The collected cells were counted by hemocytometer.
Western Blot Analyses. Cell lysates or tissue pieces were prepared by adding
protease and phosphatase inhibitor mixture in RIPA buffer and centrifuging for
10 min at 12,000 rpm to removed debris. Lysate of 15,000 FACS-sorted cells per
well were loaded into each lane of a 4 to 12% Tris gel (Bio-Rad) and subjected
to electrophoresis. After blotting, nitrocellulose-membranes (Bio-Rad) were
blocked for 1 h (milkpowder 5% in TBS/tween 0.1 to 0.2%) and incubated with
primary antibodies (Stat1, Cell Signaling ref. 14994T; P65, Cell Signaling ref.
4764S). Binding of secondary, HRP-antibodies were visualized by ECL or ECL
plus chemiluminescent (Amersham). After densitometric analyses with ImageJ,
optical density values were expressed as arbitrary units and normalized for
protein loading, as described in the figure legends.
In Vitro PBMC Culture Studies. A total of 0.5 × 106 PBMC were plated per well
in 48-well plates in culture medium consisted of Roswell Park Memorial Institute (RPMI) 1640 (Invitrogen) supplemented with L-glutamine (2 mmol/L),
sodium pyruvate (1 mmol/L), nonessential amino acids (0.1 mmol/L), penicillin (100 U/mL), streptomycin (0.1 mg/mL), 2-mercaptoethanol (1 μL of
stock), and 10% fetal bovine serum (FBS). Next, 10 ng/mL IL-4, and 50 ng/mL
granulocyte-monocyte colony-stimulating factor (GM-CSF), with or without
20 ng/mL of interferon-γ (IFN-γ) was added to wells. The culture medium was
changed every 48 h, and cells were harvested at 72 h for flow cytometry analysis.
In Vitro Cell Migration Assay. To determine the infiltrative capacity of blood
CD11c+ CD88+ myeloid cells in response to activation by IFN-γ and expression
of CD317, an in vitro Boyden chamber assay was used. This assay is modified
from the methods described previously (11). In brief, the Boyden chamber
(Transwell Permeable Supports, Corning) consists of two compartments separated by a polycarbonate membrane filter (6.5 mm in diameter, with 3-μm
pores) coated on its upper surface with fibronectin (Corning, Discovery laboratory ware, ref#: 354008, LOT:0167009; 10 μg/cm2). A total of 5 × 105 PBMC,
collected from the blood of C57BL/6 mice 10 d postimmunization with
MOGp35-55, suspended in 100 μL culture medium (see above), was added to the
upper chamber. Half of the chambers also received and extra treatment of
20 ng/mL IFN-γ in the upper and lower compartments. The phenotype of cells
added to the upper chamber was determined by flow cytometry prior to incubation. Following incubation for 72 h at 37 °C, the contents of both upper
and lower chambers were collected separately, and the CD45+ and CD45+
CD11c+ CD88+ cells were phenotyped using multiparameter flow cytometer.
Multiparameter Flow Cytometry. A total of 1 × 106 mononuclear cells suspended in PBS were stained using fixable viability dye (Zombie NIR-BioLegend
Cat#: 423105/423106) or (Zombie Aqua-BioLegend, Cat#: 423101/423102), and
incubated for 15 min at room temperature following manufacturer’s recommendation. Cells were then washed using 2% FBS-PBS (FACs buffer) at
1,500 rpm for 5 min, followed by incubation with 1 μg Fc Block (anti-CD16/32,
Tonbo Biosciences) for 15 min at 4 °C. Cells were then stained with the following antibodies: CD45 (Alexa Flour 700-BioLegend, Clone: 30-F11 or APC/Fire
750-BioLegend Clone: 13/2.3), CD11b (V450-BD Horizon, Clone: M1/70), CD19
(BV510-Biolegend, clone: 6D5), CD3 (V500-BD Horizon, clone: 500A2), CD4
(PE-BioLegend, clone: GK1.5), CD8 (APC-BD Pharmingen, clone: 53-6.7) CD11c
(APC-BioLegend, clone: N418 or BV605-BioLegend, clone: N418), MHCII
(BV785, BioLegend, clone: M5/114.15.2 or BV711-BioLegend, clone: M5/
114,15.2), CD49d (α4-integrin; FITC, BioLegend, clone: R1-2), CD88 (PE, BioLegend, clone: 20/70), CD317 (BV421, BioLegend, clone: 927 or PercpCy5.5BioLegend, clone: 927) CD26 (FITC, BioLegend, clone: H194-112), CD86 (BV421,
BioLegend, clone: GL-1), Iba-1 (Alexa Flour 594, Santa Cruz Biotechnology,
clone: 1022-5), TMEM-119 (Alexa Fluor 488, Invitrogen, clone: V3RT1G0sz),
CX3CR1 (BV421, BioLegend, clone: SA011F11) for 45 min at 4 °C. Events were
recorded via BD FACS LSR Fortessa (The Moody Foundation Flow Cytometry
Facility, University of Texas Southwestern, Dallas, TX), equipped with Diva

Manouchehri et al.
CD11c+CD88+CD317+ myeloid cells are critical mediators of persistent CNS autoimmunity

T Cell Proliferation Assay. To determine the capability of APCs to present CD4+
T cells with autoantigens, flow cytometry proliferation assays using the
fluorescent dye carboxyfluorescein succinimidyl ester (CFSE) were performed. Ten days after active immunization, spleens and lymph nodes from
CD11c.Cre+/−ITGA4fl/fl mice and WT controls were harvested and processed
into single-cell suspensions, as described above. Splenocytes and lymphocytes were stained with CFSE and plated at 1 × 106 cells per well. The cells
were then restimulated with 10 μg/mL of MOGp35-55 and incubated at 37 °C
for 5 d. Concanavalin A (Con A) at a concentration of 2 mg/mL and media
were used as controls. On day 6 the cells were collected, blocked with anti-Fc
block antibody, stained with APC CD4 antibody, and acquired and analyzed
by flow cytometry.
RNA Sequencing and Analysis. We analyzed our own published single-cell
RNA-sequencing (scRNA-seq) data to determine the expression of specific
genes among human PBMCs and cerebral spinal fluid (CSF) cells from a set of
subjects with neuroinflammation (12). Briefly, this dataset includes two
subjects with untreated relapsing remitting MS, one subject with anti-MOG
disorder, and two subjects positive for the HIV. The data for these latter two
subjects was originally derived from Farhadian et al. (13). For those subjects
whose samples were collected at Washington University School of Medicine
in St. Louis, all studies were approved by the Washington University in St.
Louis Institutional Review Board. Using our previously employed analysis
pipeline on the 23,363 PBMCs and 14,179 CSF cells combined from all subjects, we analyzed expression of ITGAX, C5AR1, and BST2. Expression was
visualized after construction of a Uniform Manifold Approximation and
Projection (UMAP) to visualize single cells in two dimensions (12).
Statistical Analysis. Groups were compared for normality using the
Kolmogorov–Smirnov test. Normally distributed data were compared using
unpaired two-sided Student t test. Holm–Sidak post hoc analysis was performed
to correct in case of multiple comparisons. All statistical analyses were two-sided
and a P value of less than 0.05 was set as the level of statistical significance. In
the figures, P values are shown as follows: *P = 0.05; **P = 0.005; *** P =
0.0005; ****P = 0.00005; *****P = 0.000005. Each experiment was repeated at
least once. All analyses were performed with Prism 8 (Graphpad).

Results
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Reduction of α4-Integrin Expression in Naïve CD11c.Cre+/−ITGA4fl/fl
Mice. We first assessed the effectiveness of Cre-Lox recombina-

tion on the expression of α4-integrin on the surface of CD11c+
leukocytes in CD11c.Cre+/−ITGA4fl/fl mice. The percentage of α4integrin expressing CD11c+ leukocytes, collected from primary
and secondary lymphoid compartments of naïve WT and
CD11c.Cre+/−ITGA4fl/fl mice was assessed using ex vivo flow
cytometry. When compared with naïve WT controls, naïve
CD11c.Cre+/−ITGA4fl/fl mice had a significantly lower frequency
of CD11c+ cells expressing α4-integrin in spleen (Fig. 1A), lymph
nodes (Fig. 1B), bone marrow (Fig. 1C), and blood (Fig. 1D) (P <
0.0005). This observation confirms that Cre-mediated gene recombination diminished the expression of α4-integrin in CD11c.Cre+/−ITGA4fl/fl mice. In order to ascertain that CD11c.Cre+/−ITGA4fl/fl mice
do not have altered absolute CD11c+ cell numbers, we assessed the
percentage of CD11c+ cells from total viable cells in different
compartments (Fig. 1 E–H) and compared them to controls. The
percentage of CD11c+ cells in the spleen (Fig. 1E) of
CD11c.Cre+/−ITGA4fl/fl mice was significantly higher than WT
controls (P < 0.05); however, there was no difference between
the two groups regarding the percentage of total CD11c+ cells in
other compartments. We also confirmed a similar α4-integrin
expression by CD11c+ leukocytes between WT and ITGA4fl/fl

mice across multiple generations, which were found to be indistinguishable. In subsequent experiments, we only compared
results between CD11c.Cre+/−ITGA4fl/fl mice and WT controls.
Clinical Onset of Active EAE Is Delayed in CD11c.Cre+/−ITGA4fl/fl Mice.

Based on our observations in a postautopsy study of progressive
multifocal leukoencephalopathy related to natalizumab therapy
(4) and the critical role of DC in the initiation and perpetuation
of CNS autoimmunity, we hypothesized that limited expression
of α4-integrin by CD11c+ cells would lead to reduction of severity of clinical EAE scores. Active EAE was induced in
CD11c.Cre+/−ITGA4fl/fl mice and WT controls by immunization
with MOGp35-55 in CFA. There was no significant difference
between CD11c.Cre+/−ITGA4fl/fl mice and WT controls regarding disease severity following active immunization (Fig. 2A).
However, the onset of clinical EAE was significantly and reproducibly delayed by at least 1 d in CD11c.Cre+/−ITGA4fl/fl
mice as compared with WT controls (Fig. 2B). Going forward,
we will refer to the delay in disease onset as “EAE onset lag.”
Moreover, we will refer to an EAE phenotype that continues
beyond a brief monophasic clinical episode as “persistent clinical
EAE.” The EAE onset lag allowed us to characterize cellular
events in relevant tissues during the preclinical stage and the
early onset of EAE in CD11c.Cre+/−ITGA4fl/fl mice in comparison to WT controls, and characterize the contribution of immune cell subsets. Ex vivo flow cytometry analyses of the
peripheral lymphoid tissues and CNS compartment during acute
and ongoing EAE stages were performed.
Antigen Presentation Is Intact in CD11c.Cre+/−ITGA4fl/fl Mice. Previous

studies indicated that blocking very late-activating antigen 4
(VLA-4; α4β1-integrin) with mAb negatively impacted the ability
of CD4+ T cells to proliferate, perhaps suggesting a role for α4integrin as a costimulatory molecule (14, 15). We assessed this in
CD11c.Cre+/−ITGA4fl/fl mice and WT controls through flow
cytometry-based recall proliferation assays. MOGp35-55–specific
CD4+ T cells were cocultured with different ratios of CD11c+
APC harvested from CD11c.Cre+/−ITGA4fl/fl mice and WT controls. Ex vivo flow cytometry assessment of the CD4+ T cells
proliferation based on CFSE dilution indicated that there was no
significant difference between CD11c.Cre+/−ITGA4fl/fl mice and
WT controls regarding the recall response by the CD4+ T cells
(Fig. 2C). This suggested that antigen (Ag) presentation and T cell
activation remained intact in CD11c.Cre+/−ITGA4fl/fl mice, despite a significantly lower expression of α4-integrin by APC.
Leukocyte Composition aside from the CD11c Cell Lineage Is Unaltered
in CD11c.Cre+/−ITGA4fl/fl Mice. Next, we investigated whether the

delayed onset of clinical EAE in CD11c.Cre+/−ITGA4fl/fl mice was
accompanied by an altered composition of leukocytes in different
compartments. Flow cytometry analysis of immune cell populations revealed that leukocyte subtypes including CD45+,
CD19+, CD4+, and CD8+ cells, from CD11c.Cre+/−ITGA4fl/fl
mice and WT controls, had similar composition in different
compartments during naïve states as well as during acute and
persistent clinical EAE (SI Appendix, Fig. S2). Few CD45hi cells
were detectable within naïve CNS tissues from both
CD11c.Cre+/−ITGA4fl/fl mice and WT controls, while CD45int
cells were present in both (SI Appendix, Fig. S3A); following the
onset of clinical EAE in both groups, CD45hi cells were abundantly present inside the CNS compartment (SI Appendix, Fig.
S3B). These observations suggest that the observed EAE onset lag
was not driven by impaired access of immune cell outside the
CD11c+ lineage to the CNS compartment.
CD11c+ Cells Sequester in Peripheral Blood Prior to the Onset of Clinical
Active EAE. As shown earlier, we observed that the onset of clinical

EAE following active immunization was consistently delayed in
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acquisition software (BD Bioscience). For FACS sorting, BD FACSARIA-II SORP
(The Moody Foundation Flow Cytometry Facility, University of Texas Southwestern, Dallas, TX) was utilized. Cells were gated according to morphology
side scatter (SSC-A) vs. forward scatter (FSC-A). Doublets were excluded (FSC-A
vs. FSC-H and SSC-A vs. SSC-H). Live cells were selected using the viability dye.
The complete gating strategy is presented in SI Appendix, Fig. S1. Gating for
FACS sorting consisted of live singlet CD45hiCD11c+MHCII+CD88+CD317+ cells
or live singlet CD45intCD11b+ cells as microglia. In each sample, a minimum of
50 × 103 live events were recorded. FlowJo software (BD Bioscience) was used
for data analysis.
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Fig. 1. CD11c.Cre+/−ITGA4fl/fl mice exhibited reduced expression of α4-integrin by CD11c+ cells. The mean ± SD of α4-integrin (CD49d)-expressing CD11c+ cells
(%) from total 50 × 103 recorded viable cells in (A) spleen, (B) lymph node, (C) bone marrow, and (D) blood of naïve WT and CD11c.Cre+/−ITGA4fl/fl mice is
shown (n = 9 experimental animals per group; data show the pooled analysis of all study cohorts). The α4-integrin expression in CD11c.Cre+/−ITGA4fl/fl mice
compared to C57BL/6 WT controls is significantly reduced in all compartments (***P < 0.0005). The absolute number as a percentage of CD11c+ cells from total
viable cells is not reduced in CD11c.Cre+/−ITGA4fl/fl mice. The mean ± SD of CD11c+ cells (%) from total 50 × 103 recorded viable cells in (E) spleen, (F) lymph
node, (G) bone marrow, and (H) blood is shown (n = 9 experimental animals per group; data show the pooled analysis of all study cohorts). The percentage of
CD11c+ cells was significantly higher in the spleen among CD11c.Cre+/−ITGA4fl/fl mice (*P < 0.05). There was no difference between the two groups regarding
the percentage of CD11c+ cells in other compartments.

the CD11c.Cre+/−ITGA4fl/fl group. The EAE onset lag provided a
window for studying the composition of the inflammatory milieu in
different compartments. Using ex vivo flow cytometry, we compared the percentage of live CD45+MHCII+CD11c+ cells collected from the peripheral blood and CNS (brain and spinal cord)
of CD11c.Cre+/−ITGA4fl/fl mice and WT controls at two time points
following induction of active EAE. The cells were collected from
both groups upon the onset of clinical EAE among the WT controls
on day 11 postimmunization (Fig. 2D). In this setting, CD11c+ cells
were significantly more frequent in the blood of CD11c.Cre+/−ITGA4fl/fl mice compared to WT controls (Fig. 2E) (P < 0.00005);
simultaneously, these cells were significantly more abundant in the
brain (Fig. 2F) and spinal cord (Fig. 2G) of the WT controls (P <
0.005). Subsequently, cells were collected from mice in both groups
at the onset of clinical EAE among the CD11c.Cre+/−ITGA4fl/fl
mice on day 14 postimmunization (Fig. 2H). There were no significant differences between the frequencies of CD11c+ cells inside
the peripheral circulation (Fig. 2I), brain (Fig. 2J), and spinal cord
(Fig. 2K) of the CD11c.Cre+/−ITGA4fl/fl mice compared to WT
controls. Taken together, these findings indicate that the clinical
onset of EAE is closely related to the increased appearance of
CD11c+ cells inside the CNS compartment. The concomitant disappearance of these cells from the blood suggests that CD11c+ cells
inside the CNS originated from cells entering from the peripheral
compartment.
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CD11c+ Cells and CD11c+CD88+ Cells Distribute Similarly Among
Tissues during Active EAE. We observed that the onset of clinical

EAE was preceded by the accumulation of CD11c+ cells in the
blood, and their subsequent appearance inside the CNS was associated with the onset of clinical disease. Next, we wanted to
further characterize immunologic traits of these cells. Bone
marrow-derived CD11c+ myeloid cells in the blood are comprised
to a significant extent of CD88+ monocyte-derived cells (16–18).
4 of 11 | PNAS
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Using ex vivo flow cytometry, we assessed the percentage of CD88
expressing CD11c+ cells collected from the blood and CNS of
CD11c.Cre+/−ITGA4fl/fl mice and WT controls. In both groups,
the majority of CD11c+ cells in the blood and CNS also expressed
CD88. At the time of the onset of clinical EAE in the WT control
group (Fig. 2D) (day 11 postimmunization), CD11c+ CD88+ cells
accumulated in the blood of CD11c.Cre+/−ITGA4fl/fl mice
(Fig. 2L) (P < 0.00005), while they were significantly more frequent
inside the brain (Fig. 2M) and spinal cord (Fig. 2N) of WT controls
(P < 0.005). Subsequently, following the onset of clinical EAE in
CD11c.Cre+/−ITGA4fl/fl mice (Fig. 2H) (day 14 postimmunization),
the percentage of CD11c+ CD88+ cells in the blood was diminished
(Fig. 2O), while it was increased in the brain (Fig. 2P) and spinal
cord (Fig. 2Q). At that time, there were no differences between the
two experimental groups in any of these compartments.
CD11c+CD88+ Cells Express CD317 inside the CNS but Not in Blood. We

observed that CD11c+ cells from CD11c.Cre+/−ITGA4fl/fl mice
were initially delayed from gaining access to the CNS, but ultimately accumulated inside the brain and spinal cord of
CD11c.Cre+/−ITGA4fl/fl mice (Fig. 2). This suggested redundancy
in adhesion molecules by CD11c+ myeloid cells. CD317 is a lipid
raft-associated glycosyl-phosphatidylinositol (gpi)-anchored protein
that is constitutively expressed by plasmacytoid DC, mature B cells,
plasma cells, and other leukocytes (19, 20). More recently, CD317
has also been shown to function as an adhesion molecule for myeloid cells (21). To determine whether CD317 is up-regulated by
CD11c+CD88+ cells upon entry into the CNS and serves as an
adhesion molecule, we assessed its expression by CD11c+ cells in
our model. During active EAE, we found that CD317-expressing
CD11c+CD88+ cells in the peripheral circulation were significantly
less frequent (P < 0.0005) than CD11c+CD88+CD317− cells
(Fig. 3A). In contrast, the percentage of CD11c+CD88+ cells
expressing CD317 was significantly higher than the percentage of
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Fig. 2. The onset of active EAE is consistently delayed among the CD11c.Cre+/−ITGA4fl/fl mice. (A) The mean ± SE of clinical EAE following active immunization are presented (n = 24 experimental animals per group; data display pooled analysis of all study cohorts). (A and B) The onset of disease was significantly delayed in the CD11c.Cre+/−ITGA4fl/fl group (*P < 0.05). (C) The percentage (mean ± SD) of proliferating Ag-specific CD4+ T cells cocultured with
different dilutions of CD11c+ splenocytes from CD11c.Cre+/−ITGA4fl/fl mice and WT controls is shown. There was no significant difference between the two
groups. Clinical EAE is preceded by accumulation of CD11c+ cells in peripheral blood. The mean ± SD of percentage of CD11c+ and CD11c+CD88+ cells from
total 50 × 103 recorded viable cells upon the onset of actively induced clinical EAE in (D) C57BL/6 WT controls (day 11 postimmunization), in (E and L) blood, (F
and M) brain, and (G and N) spinal cord, and after the onset of clinical EAE in CD11c.Cre+/−ITGA4fl/fl mice (H) in (I and O) blood, (J and P) brain, and (K and Q)
spinal cord and is shown (n = 8 experimental animals per group; data show pooled analysis of all study cohorts). (E and I) There was a significant sequestration
of CD11c+ and CD11c+CD88+cells in the blood of CD11c.Cre+/−ITGA4fl/fl compared to controls upon the onset of clinical EAE (****P < 0.00005), while CD11c+
cells were significantly more frequent in the (F and J) brain and (G and K) spinal cord of WT mice (**P = 0.005). (F–H) There was no difference between the
two groups in any of the compartments after the start of the clinical EAE among the CD11c.Cre+/−ITGA4fl/fl mice (day 14 postimmunization; P > 0.05).

CD11c+ CD88+ cells not expressing CD317 in the brain (Fig. 3B)
and spinal cord (Fig. 3C) (P < 0.0005). Together, these observations suggest that CD11c+CD88+ cells in the peripheral circulation
start expressing CD317 upon entry into the CNS compartment at
the onset of clinical EAE.
The expression of CD317 is inducible through engagement of
signal transducer and activator of transcription (STAT) following exposure to type I or type II IFN (22–24). To investigate
whether CNS CD11c+CD88+CD317+ cells originate from blood
CD11c+CD88+ cells at the onset of clinical EAE, we collected
PBMC from WT mice immunized with MOGp35-55, prior to the
expected onset of clinical EAE (day 10 postimmunization). In
vitro culture was performed with or without stimulation with
IFN-γ. Subsequent flow cytometry analysis of the cultured cells
revealed that CD11c+CD88+ cells that were exposed to IFN-γ in
culture up-regulated CD317 on their cell surface (Fig. 3D). The
percentage of CD11c+CD88+CD317+ was significantly higher in the
IFN-γ–treated group (P < 0.0005). Interestingly, the fraction of
CD11c+CD88+ cells expressing CD317 after in vitro exposure to
IFN-γ was comparable to that of these cells observed in the CNS
compartment during clinical EAE in both experimental groups, and
significantly higher than that of blood CD11c+CD88+ cells (Fig. 3E).
IFN-γ Promotes the Migration of CD11c+CD88+CD317+ across Biological
Barriers. Once it was established that IFN-γ mediates the expres-

sion of CD317 in blood CD11c+CD88+ cells, we aimed to assess

whether IFN-γ impacts migration capacity. PBMC from C57BL/6
WT mice immunized with MOGp35-55 were collected and inserted
into the upper compartment of a Boyden chamber with or without
IFN-γ. We were able to show that IFN-γ significantly enhanced
the number of CD11c+CD88+CD317+ cells that migrated to the
bottom chamber after 72 h (Fig. 3F).
Proinflammatory Signaling Pathways Are Activated in CD11c+CD88+CD317+
Cells. Our previous observation suggests a proinflammatory role for

CD11c+CD88+CD317+ cells in EAE. Using Western blot analyses,
we assessed the expression of proinflammatory STAT-1 and NF-κB
transcription factors among these cells and compared them to
that of the CNS microglia of these mice during acute EAE (day 14
postimmunization) as well as naïve microglia. We were able to
show that compared to naïve and postacute EAE microglia,
CD11c+CD88+CD317+ cells expressed significantly higher levels
of STAT-1 (Fig. 3G) and NF-κB (Fig. 3H) (P < 0.0005 and P <
0.005, respectively). While microglia collected from the CNS of
acute EAE mice expressed significantly higher levels of STAT-1
compared to naïve microglia (Fig. 3G) (P < 0.0005), there was no
difference regarding the expression NF-κB (Fig. 3H).
CD11c+CD88+ Cells and CD11c+CD88+CD317+ Cells Express CD11b. To
characterize blood CD11c+CD88+ cells during preclinical EAE
as well as CNS CD11c+CD88+CD317+ cells during established
EAE, we assessed both cell types for CD11b expression. CD11b
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Fig. 3. CD11c+CD88+ cells start expressing CD317 inside the CNS compartment at the onset of active clinical EAE. The mean ± SD of the percentage of
CD11c+CD88+ cells that express CD317 in (A) blood, (B) brain, and (C) spinal cord during actively induced EAE in CD11c.Cre+/−ITGA4fl/fl mice or C57BL/6 WT
controls is shown (n = 8 experimental animals per group; data show pooled analysis of all study cohorts). CD11c+CD88+ cells in the (A) blood are mostly
CD317−, while inside the (B and C) brain and spinal cord CD317+ cells constitute the majority of the CD11c+CD88+ cells (***P < 0.0005). (D) The mean ± SD of
CD11c+ CD88+CD317+ cells following in vitro culture (n =12 replicates per group; data show pooled analysis of all study cohorts). (D) IFN-γ significantly upregulates the expression of CD317 in CD11c+CD88+ cells (***P < 0.0005). (E) The mean ± SD of percentage of CD317+ cells of all CD11c+CD88+ cells is shown,
and approaches the percentage of CD317+ cells of all CD11c+CD88+ cells within the CNS of mice with clinical EAE. (F) IFN-γ enhances the migratory capability
of CD11c+CD88+CD317+ cells. There was a significant increase in the percentage of CD11c+CD88+CD317+ cells from total CD45+ cells in the bottom chamber in
the presence of IFN-γ (*P = 0.05; n = 4 replicates per group are shown). (G) CD11c+CD88+CD317+ cells inside the CNS compartment express high levels of STAT1 and NF-κB (p65) transcription factors. The mean ± SD of fold-change among CD11c+CD88+CD317+ cells for STAT-1 (G) and NF-κB (p65) (H) expression were
significantly higher compared to both naïve microglia and active EAE microglia (day 14 postimmunization) (***P < 0.0005 and **P < 0.005, respectively). The
mean ± SD of fold-change in STAT-1 was also significantly higher among the active EAE microglia compared to naïve microglia (G) (***P < 0.0005). All
Western blot experiments were conducted as triplicates.

is expressed on granulocyte, macrophages, monocytes, and natural killer cells (25). We observed that CD11c+CD88+ cells and
CD11c+CD88+CD317+ cells also express CD11b (SI Appendix,
Fig. S1), a property that has been assigned to migratory DC (25).
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Decreased EAE Severity in the Absence of CD11c+CD88+CD317+ Cells
in the CNS. In active EAE, the microenvironment outside of the

CNS in this EAE model is defined by an excess of IFN-γ (26). In
contrast, the adoptive transfer of myelin-reactive CD4+ T cells,
many of which are Th1 cells, creates an IFN-γ–rich environment
inside the CNS, but not in other tissues (27–29). MOGp35+
T cells from WT donors were transferred to
55–reactive CD4
+/−
CD11c.Cre ITGA4fl/fl and WT control recipients (Fig. 4A).
Analysis of clinical disease scores in both groups longitudinally
revealed a striking reduction of clinical disease in the CD11c.Cre+/−ITGA4fl/fl mice as compared with WT controls (P < 0.0005) (Fig. 4A).
Specifically, the disease course was substantially ameliorated and abbreviated, and devoid of the persistent clinical phase that is routinely
expected in the C57BL/6 model of EAE. Ex vivo flow cytometry
revealed that CD11c+CD88+ cells were significantly more frequent in
the blood of CD11c.Cre+/−ITGA4fl/fl mice compared to WT controls
at day 18 postadoptive transfer (Fig. 4B) (P < 0.005). Further ex vivo flow
cytometry-based characterization of immune cells in the peripheral
compartment and CNS of mice in both groups indicated that
6 of 11 | PNAS
https://doi.org/10.1073/pnas.2014492118

CD11c.Cre+/−ITGA4fl/fl mice that showed less severe disease course
also exhibited significantly lower percentage of CD11c+ cells,
CD11c+CD88+ cells, and CD11c+CD88+CD317+ cells inside the
brain (Fig. 4 C and F) and spinal cord (Fig. 4 D and G) (P < 0.005).
Interestingly, CD11c+CD88+CD317+ were extremely rare in the
blood of both CD11c.Cre+/−ITGA4fl/fl mice and WT controls
(Fig. 4E). In summary, these observations suggest an association
between the presence of CD11c+CD88+CD317+ cells inside the
CNS and the severity of acute EAE, as well as the transition to
persistent clinical EAE.
Coincident Expression of ITGAX, C5AR1, and BST2 by Human CSF
Microglia-like Cells in Neuroinflammation. After identifying the as-

sociation of CD11c+CD88+CD317+ cells with EAE disease severity, we aimed to determine whether this cell type could also be
identified in human tissues relevant to CNS autoimmunity. Using
scRNA-seq, our group previously described 20 clusters representing distinct cell populations within PBMCs and CSF of
subjects with neurologic diseases (Fig. 5A) (12). Our report, as
well as recent reports from other groups (30–32), has described a
distinct cell type within the CSF displaying the gene-expression
profile of microglia (30, 33, 34). We examined our published dataset
for the individual expression of BST2, C5AR1, and ITGAX, the
human genes encoding CD317, CD88, and CD11c (Fig. 5 B and C).
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The collective expression of these three genes was concentrated
within myeloid cell populations, most notably within CSF microglialike cells (Fig. 5D). These data suggest that a microglia-like population of cells within human CSF that expresses this combination
of genes is relevant to neuroinflammation.
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Activated, but Not Naïve, Microglia Express CD11c, CD88, and CD317.

Intrigued by the finding that expression of ITGAX, C5AR1, and
BST2 localize within human CSF microglia-like cells by transcriptomic analyses, we aimed to determine whether parenchymal microglia also express these surface markers. Due to the lack
of human CNS tissue, we decided to assess murine microglia
cells. Microglia were defined as viable CD45 intermediate (int),
CD11b+ cells (Fig. 6A). Microglia from naïve mice did not express CD88 and CD317 concomitantly (Fig. 6B). Moreover, naïve
microglia are not high expressers of MHC II and CD11c (Fig. 6C).
In contrast, microglia from mice with established active EAE express high levels of CD88 and CD317 (Fig. 6 D and F), as well as
MHC II and CD11c (Fig. 6 E and G). In summary, these data indicate that CNS CD11c+CD88+CD317+ cells associated with CNS
autoimmune disease resemble activated parenchymal microglia. We
further assessed CD45int CD11b+CD11c+CD88+CD317+ cells
defined as microglia, and CD45hi CD11c+CD88+CD317+ cells
defined as bone marrow-derived myeloid cells through ex vivo flow
cytometry (SI Appendix, Fig. S3). First, CX3CR1+ cells from CD45int
CD11c+CD88+CD317+and CD45hi CD11c+CD88+CD317+ cells
were gated for (SI Appendix, Fig. S3E). Microglia were further defined as CX3CR1+TMEM-119+Iba-1+ (SI Appendix, Fig. S3 F and

G), while nonmicroglia were further defined as CX3CR1+TMEM119−Iba-1− (SI Appendix, Fig. S3 J and K). In naïve mice and during
different stages of EAE, microglia were mostly localized within the
CD45int gate (SI Appendix, Fig. S3 H and R), while nonmicroglia were
situated within the CD45hi gate (SI Appendix, Fig. S3 L and S). Fewer
CD45int microglia expressed surface CD86 (SI Appendix, Fig. S3I)
compared to CD45hi nonmicroglia (SI Appendix, Fig. S3M).
Anti-CD317 Treatment Ameliorates EAE and Shortens Disease Duration.

To provide further evidence that CD11c+CD88+CD317+ cells are
critical for establishment of persistent clinical EAE, and are
therefore potential therapeutic targets, we administered a commercially available anti-CD317 rat anti-mouse IgG2b mAb on days
7 and 8 postactive immunization (Fig. 7A). Anti-CD317 treatment
ameliorated acute EAE, with complete resolution of clinical disease. Anti-CD317 therapy resulted in an increase of CD11c+,
CD11c+CD88+, and CD11c+CD88+CD317+cells in blood (Fig. 7B).
However, the difference in cell numbers compared to vehicle controls
group was not statistically significant. Furthermore, in the treatment
group, CD11c+, CD11c+CD88+, and CD11c+CD88+CD317+cells
in the brain (Fig. 7C) and spinal cord (Fig. 7D) were reduced compared with controls. This was statistically significant in the spinal cord
(Fig. 7D) (P < 0.005). Differences in the percentages of CD11c+ cells
and CD11c+CD88+ in the blood, brain, and spinal cord in the antiCD317 treatment group were driven by changes in the percentages of
CD11c+CD88+CD317+cells. Our observations suggest that anti-CD317
therapy in EAE diminishes the ability of CD11c+CD88+CD317+ cells to
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gain access to the CNS, reducing the severity of acute EAE and the
transition to persistent clinical EAE.
Discussion
In the present study, we investigated the effects of selective
α4-integrin deletion in CD11c+ cells in the EAE model of MS.
Our observations indicate that the appearance of CD11c+
CD88+CD317+ myeloid cells inside the CNS compartment is
required for establishment of persistent clinical EAE after active
immunization. This is further supported by the fact that reducing
the ability of these cells to gain access to the CNS via a blocking
anti-CD317 mAb also prevented persistent clinical EAE. This
suggests CD317 as a promising molecular target for treatment in
patients with MS and related disorders.
Classically, CD11c+ myeloid cells are believed to participate
in processing and presentation of antigens to Ag-specific T cells
during CNS autoimmunity in secondary lymphoid organs and the
brain and spinal cord (2). Based on our results, we suggest that
the role of CD11c+CD88+CD317+ cells in EAE pathogenesis
may be largely independent of antigen presentation. CD88+ DC
were previously shown to have minimal antigen presentation
capability during active EAE as evidenced by a limited ability to
induce T cell proliferation to recall antigens (18). In fact, initiation of clinical EAE, which requires Ag processing and presentation in peripheral lymphatic tissues, is mainly driven by
classic tissue-resident classic DC, characterized by their expression of CD26 (18). We showed in our model that Ag presentation and ability to induce T cell proliferation was maintained
despite the deletion of α4-integrin in CD11c cells in Cre+/−ITGA4fl/fl mice. Furthermore, our results indicate that the pathogenic role of CD11c+CD88+CD317+ cells in EAE appears
dependent on their physical presence in the inflammatory environment in the CNS, since inhibiting their entry into the CNS
compartment with anti-CD317 mAb ameliorated clinical EAE,
but did not eliminate these cells from the peripheral blood.
CD11c+ cells from CD11c.Cre+/−ITGA4fl/fl mice have a significantly reduced expression of α4-integrin. Despite this observation, CD11c+ cells are merely delayed in, but not prevented
from, gaining access to the CNS. Ultimately, CD11c+ cells are
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abundantly present inside the brain and spinal cord of
CD11c.Cre+/−ITGA4fl/fl mice at EAE disease onset following active immunization. We posit that this intriguing observation may
point to a redundancy in the usage of adhesion molecules in
CD11c+ myeloid cells in gaining access to the CNS compartment.
Work by other investigators suggests that macrophages utilize
CD317 as an adhesion molecule to gain access to their target
tissue during inflammation (21). In our study, CD11c+CD88+
cells circulated and sequestered in the peripheral blood of
CD11c.Cre+/−ITGA4fl/fl mice, and it was only after they acquired
the expression of CD317 that they gained access to the CNS. The
exact role and mechanism how CD317 expression endows these
cells with access to the CNS, and whether it serves directly as an
alternative adhesion molecule that substitutes or complements α4integrin, needs further study.
CD317 is constitutively expressed by many cell types, including
myeloid cells and B-lymphocytes (19, 20). There are speciesspecific differences regarding the expression of CD317. While
human plasmacytoid DC express low amounts of surface CD317,
this does not similarly apply to plasmacytoid DCs in mice (31).
The promoter region of CD317 contains multiple cis-regulatory
elements for transcription factors, including STAT (32, 35).
Engagement of STAT induces the expression of CD317 after
exposure to type I and type II IFNs (22–24), consistent with our in vitro
data, and lending support to the concept that CD11c+CD88+ cells in
the blood can up-regulate CD317 during active EAE under the influence of IFN-γ. In CD11c+CD88+CD317+ cells, STAT-1 and NF-κB
expression is up-regulated compared to naïve microglia or active EAE
microglia, supporting their role as proinflammatory cells during EAE.
One ligand of CD317 that has been identified as the surface molecule
immunoglobulin-like transcript 7 (ILT7) (36, 37), which is expressed by
immature plasmacytoid DC (31). Furthermore, the adhesion of myeloid cells to endothelial cells appears to be partially mediated by CD317
on endothelial cells (21), which presumably interact with ILT7 on
myeloid cells. Thus, the effects we observed on clinical EAE and the
distribution of CD11c+CD88+CD317+ cells after anti-CD317 therapy
may be due to binding of anti-CD317 mAb to CD11c+CD88+
CD317+cells in blood, or to endothelial cells in the CNS, or both. Our
data favor an effect of anti-CD317 on CD11c+CD88+CD317+cells, as
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data indicates that access to IFN-γ significantly increases the
migratory capability of CD11c+CD88+CD317+ cells across biological
barriers.
Interestingly, our human CSF transcriptome analyses placed
ITGAX+C5AR1+BST2+ cells within a population of myeloid cells
that was previously defined as CSF microglia (12, 13, 38, 39). We
found that activated, but not naive murine microglia, concomitantly express CD11c, CD88, and CD317. We believe these data
indicate that bone marrow-derived CNS CD11c+CD88+CD317+
cells associated with CNS autoimmune disease resemble activated
parenchymal microglia. At this point, it is unclear whether these
are independent cell populations with similar phenotypes and
function, or whether there is a sequential development from one
to the other. Future research will focus on determining which of
the murine myeloid subsets in EAE recently defined by scRNAseq express CD317 (40).
Proinflammatory myeloid cells during the pathogenesis of
EAE have been described previously. Along these lines, central
roles were reported for CCR2+ myeloid cells (41), tissue resident
classic DC (42), microglia vs. peripherally seeded monocytederived DC (18), and proinflammatory iNOS+ macrophages vs.
antiinflammatory Arg-1+ macrophages (42). Our observations
add to the complexity of categorizing myeloid cell populations
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the differences in the percentages of CD11c+ cells and CD11c+CD88+
in the blood, brain, and spinal cord in the anti-CD317 treatment group
were driven by changes in the percentages of CD11c+CD88+CD317+
cells. It was difficult to detect CD11c+CD88+CD317+cells in blood.
These observations suggest an expression of CD317 on CD11c+CD88+
in the blood immediately prior to their egress from the blood into
the CNS.
Expression of CD317 by CD11c+CD88+ cells is partially induced by IFN-γ. This was shown through in vitro culture of
CD11c+CD88+ cells. This observation provides one possible
explanation for the distinct clinical phenotypes observed in active
EAE vs. adoptive transfer EAE in CD11c.Cre+/−ITGA4fl/fl mice.
In active EAE, the activation of CD4+ T cells by myelin autoantigen and CFA results in the generation of autoreactive Th17
and Th1 cells, the latter producers of IFN-γ. Consequently, a
microenvironment is created outside of the CNS that provides
exposure to IFN-γ that may up-regulate CD317 on CD11c+
CD88+ cells in active EAE. However, the adoptive transfer of
myelin-reactive CD4+ T cells, which includes both Th1 and Th17
cells, provides IFN-γ signaling preferentially inside the CNS after
the T cells have migrated there (27–29). Thus, in the setting of
adoptive transfer EAE, CD11c+CD88+ cells lack IFN-γ outside
the CNS to induce CD317. Our in vitro Boyden chamber assay
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Fig. 7. Anti-CD317 treatment prevents established EAE. (A) EAE was actively induced in C57BL/6 WT mice. The mean ± SE of clinical EAE scores following the
injection of anti-CD317 mAb in active EAE are shown (n = 10 experimental animals per group; data show pooled analysis from all study cohorts). There was a
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into DC or monocytes/macrophages based on surface markers
alone. Our results suggest that detailed morphological and functional profiling is required to provide a more profound categorization and function-based understanding of the role of these cells
during different stages of EAE.
In conclusion, here we show that CD11c+CD88+CD317+ cells
appear to be critical mediators of disease in EAE that are intimately associated with the onset of disease. These cells originate
from peripheral myeloid cells and their disease-propagating effects can be successfully antagonized using an mAb directed
against CD317. We speculate that this pathway holds potential as
a novel therapeutic option in MS.
Data Availability. All study data are included in the article and
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